We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-1.07%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.91B
AUM Growth
-$338M
Cap. Flow
-$272M
Cap. Flow %
-9.35%
Top 10 Hldgs %
56.63%
Holding
45
New
6
Increased
11
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$87.5M
2
MRK icon
Merck
MRK
+$79.6M
3
GILD icon
Gilead Sciences
GILD
+$79.2M
4
INCY icon
Incyte
INCY
+$60.7M
5
VTRS icon
Viatris
VTRS
+$53.4M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$113M
2
HCA icon
HCA Healthcare
HCA
+$109M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.9M
4
ALKS icon
Alkermes
ALKS
+$37.5M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$34.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.2%
2 Technology 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTRS icon
1
Viatris
VTRS
$20.8B
$216M 7.44%
16,000,000
+4,000,000
+33% +$53.4M
UHS icon
2
Universal Health Services
UHS
$10.2B
$214M 7.35%
1,650,000
+200,000
+14% +$25.7M
MRK icon
3
Merck
MRK
$322B
$192M 6.58%
2,500,000
+1,000,000
+67% +$79.6M
SNY icon
4
Sanofi
SNY
$107B
$190M 6.54%
3,800,000
+800,000
+27% +$39.6M
WBA
5
DELISTED
Walgreens Boots Alliance
WBA
$183M 6.27%
3,500,000
-500,000
-13% -$24.2M
GILD icon
6
Gilead Sciences
GILD
$165B
$163M 5.61%
2,250,000
+1,150,000
+105% +$79.2M
MRK icon
7
CALL
Merck
MRK
$322B
$153M 5.27%
2,000,000
– –
ZBH icon
8
Zimmer Biomet
ZBH
$18.8B
$127M 4.37%
1,030,000
+283,157
+38% +$37.1M
GSK icon
9
GSK
GSK
$107B
$110M 3.79%
2,000,000
-200,000
-9% -$10.4M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$123B
$98.8M 3.4%
+450,000
New +$87.5M
THC icon
11
Tenet Healthcare
THC
$22.2B
$98M 3.37%
1,200,000
-1,550,000
-56% -$113M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.9B
$89.7M 3.08%
1,015,000
-135,000
-12% -$11.1M
NVS icon
13
CALL
Novartis
NVS
$302B
$87.5M 3.01%
1,000,000
-1,000,000
-50% -$83M
CHNG
14
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$85.5M 2.94%
4,000,000
– –
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$84.3M 2.9%
575,000
+125,000
+28% +$19.4M
BKD icon
16
Brookdale Senior Living
BKD
$3.55B
$82.6M 2.84%
16,000,000
– –
MYGN icon
17
Myriad Genetics
MYGN
$476M
$75.9M 2.61%
2,750,000
– –
SNY icon
18
CALL
Sanofi
SNY
$107B
$75.2M 2.58%
1,500,000
+500,000
+50% +$24.7M
SRPT icon
19
Sarepta Therapeutics
SRPT
$1.64B
$74.3M 2.55%
825,000
+325,000
+65% +$27.8M
PRGO icon
20
Perrigo
PRGO
$1.44B
$67.1M 2.31%
1,725,000
-775,000
-31% -$32.6M
INCY icon
21
Incyte
INCY
$25.8B
$66.1M 2.27%
+900,000
New +$60.7M
BIIB icon
22
Biogen
BIIB
$30.9B
$60M 2.06%
250,000
+175,000
+233% +$45M
NKTR icon
23
Nektar Therapeutics
NKTR
$2.39B
$50.7M 1.74%
250,000
– –
IONS icon
24
Ionis Pharmaceuticals
IONS
$8.93B
$42.3M 1.45%
1,390,000
-1,110,000
-44% -$34.9M
OSUR icon
25
OraSure Technologies
OSUR
$273M
$36.9M 1.27%
4,250,000
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Camber Capital Management held 45 positions worth $2.91B, down 10% from $3.25B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Camber Capital Management withdrew a net $272M in Q4 2021, closing 6 positions and reducing 15 holdings. Its most notable exit was HCA Healthcare, an estimated $109M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Technology.

Against the trend, Camber Capital Management opened a new position in Vertex Pharmaceuticals worth $98.8M.

  • Camber Capital Management's largest Q4 2021 buy was Vertex Pharmaceuticals: 450,000 shares worth $98.8M.
  • Camber Capital Management added most to Merck in Q4 2021, an estimated $79.6M increase.
  • Camber Capital Management's biggest Q4 2021 reduction was Tenet Healthcare, cutting an estimated $113M.
  • Camber Capital Management fully exited HCA Healthcare in Q4 2021, selling an estimated $109M.
  • Camber Capital Management's ten largest holdings make up 57% of its $2.91B portfolio in Q4 2021.
  • Camber Capital Management opened 6 new positions and closed 6 in Q4 2021.
  • Camber Capital Management's portfolio value fell 10% quarter-over-quarter to $2.91B.

Based on Camber Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.